CKD Research

"CKD Research" does not appear to be a standalone company. The closest life-science match is Chong Kun Dang, a South Korean pharmaceutical company that operates a formal research organization commonly referred to as the Chong Kun Dang Research Institute. Chong Kun Dang develops and commercializes prescription drugs, OTC medicines, and biologics, and it is advancing an internal pipeline spanning small molecules, biosimilars, antibody-drug conjugates, and vaccines. Its disclosed R&D focus includes HDAC6 inhibitor programs, metabolic and oncology assets, and biologics such as cMET-targeting ADCs and biosimilars. The company also highlights proprietary platform technologies including an HDAC6 discovery platform and the Liquistal sustained-release injectable platform. In addition to R&D, Chong Kun Dang has manufacturing operations and international expansion activities across Asia and other export markets.